Phosphoinositide 3-kinase in Health and Disease

From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here.

שנה

2010

שפה

English

סדרה

Current topics in microbiology and immunology -- v. 346

הוצאה

Springer Verlag

מהדורות

7

עמודים

306

ISBN

9783642136634

מקור הנתונים: Wikidata